leadership

Mark Herzog has spent more than two decades at the intersection of bioscience, government, and national security — helping build businesses, securing government capital, and turning promising science into deployed medical countermeasures.

Mark's career has taken him from the executive suites of commercial pharmaceutical and clinical laboratory companies to the halls of government and back — giving him a rare vantage point to develop his relationships across industry and executive branch agencies. As a senior executive, he built a medical countermeasures business unit from inception, directing the full MCM development lifecycle from business development, government contracting, all the way through FDA approval, commercialization and military and civil defense acquisition and deployment. Over the course of that work, he secured more than $100 million in U.S. government contracts, negotiated sole-source international procurement agreements, and drove sustained revenue growth in a complex, highly regulated market.

He knows this ecosystem because he has operated inside it. Mark has worked directly with the agencies and institutions that define the U.S. biodefense landscape — including the Department of Defense, BARDA, and the Defense Logistics Agency — and built lasting relationships with allied partners across NATO, the UK Ministry of Defence, Canadian Department of National Defense, and the European Commission. When he opens a door for a client, it's because he's walked through it himself.

Mark currently serves on the Executive Committee of the Medical CBRN Defense Consortium (MCDC) and remains active across the industry's most important networks, including the Medical Countermeasures Coalition (MC2), the CBRNe Industry Association, BARDA's Rapid Response Partnership Vehicle, and the Medical Technology Enterprise Consortium (MTEC).

He holds a Bachelor of Arts from the College of William & Mary and an MBA from Virginia Commonwealth University's School of Business,